Literature DB >> 3872101

Immunoregulatory effects of alpha-interferon. Effects on in-vitro antibody synthesis by lymphocytes from patients with rheumatoid arthritis.

B K Pelton, A M Denman.   

Abstract

The immunosuppressive effects of alpha-interferon (IFN) on the in-vitro synthesis of specific anti-influenza virus antibody by lymphocytes from 20 healthy donors were compared with those from 12 patients with rheumatoid arthritis. No differences were observed between the two groups. IFN suppressed the induction of in-vitro antibody synthesis by lymphocytes from rheumatoid donors but did not affect antibody synthesis once this had been initiated. Furthermore, the IFN-mediated suppression of antibody synthesised by rheumatoid lymphocytes could also be reversed by B cell helper supernatant. These findings make it unlikely that alpha-IFN affects established B cell responses characteristic of the rheumatic diseases.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3872101      PMCID: PMC1001593          DOI: 10.1136/ard.44.3.143

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  14 in total

1.  Characterization of mononuclear effector cells in human blood.

Authors:  P Hersey; A Edwards; J Edwards
Journal:  Clin Exp Immunol       Date:  1976-01       Impact factor: 4.330

2.  1958 Revision of diagnostic criteria for rheumatoid arthritis.

Authors:  M W ROPES; G A BENNETT; S COBB; R JACOX; R A JESSAR
Journal:  Bull Rheum Dis       Date:  1958-12

3.  Interferon treatment of NZB mice: accelerated progression of autoimmune disease.

Authors:  H Heremans; A Billiau; A Colombatti; J Hilgers; P de Somer
Journal:  Infect Immun       Date:  1978-09       Impact factor: 3.441

4.  Susceptibility of human lymphocyte populations to infection by herpes simplex virus.

Authors:  B K Pelton; R C Imrie; A M Denman
Journal:  Immunology       Date:  1977-05       Impact factor: 7.397

5.  The effect of exogenous interferon: acceleration of autoimmune and renal diseases in (NZB/W) F1 mice.

Authors:  C Adam; Y Thoua; P Ronco; P Verroust; M Tovey; L Morel-Maroger
Journal:  Clin Exp Immunol       Date:  1980-05       Impact factor: 4.330

6.  Multiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis.

Authors:  J J Hooks; G W Jordan; T Cupps; H M Moutsopoulos; A S Fauci; A L Notkins
Journal:  Arthritis Rheum       Date:  1982-04

7.  Immune interferon in the circulation of patients with autoimmune disease.

Authors:  J J Hooks; H M Moutsopoulos; S A Geis; N I Stahl; J L Decker; A L Notkins
Journal:  N Engl J Med       Date:  1979-07-05       Impact factor: 91.245

8.  Serum interferon levels in patients with systemic lupus erythematosus.

Authors:  S R Ytterberg; T J Schnitzer
Journal:  Arthritis Rheum       Date:  1982-04

9.  Systemic lupus erythematosus: presence in human serum of an unusual acid-labile leukocyte interferon.

Authors:  O T Preble; R J Black; R M Friedman; J H Klippel; J Vilcek
Journal:  Science       Date:  1982-04-23       Impact factor: 47.728

10.  Sheep red cell binding to human lymphocytes treated with neuraminidase; enhancement of T cell binding and identification of a subpopulation of B cells.

Authors:  Z Bentwich; S D Douglas; E Skutelsky; H G Kunkel
Journal:  J Exp Med       Date:  1973-06-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.